Bone Broth Clinical Study: Digestive Wellbeing & Intestinal Permeability Research | Broth & Co

Bone Broth Clinical Study: Digestive Wellbeing & Intestinal Permeability Research | Broth & Co

Clinical Study Summary

Effect of Broth & Co Beef Bone Broth on Gastrointestinal Symptoms and Intestinal Permeability: The Bone Broth Gut Study

Conducted by the National Institute of Integrative Medicine (NIIM)

Chief Investigator
A/Prof Karin Ried, PhD, MSc, GDPH, Cert Integ Med
Director of Research, National Institute of Integrative Medicine (NIIM)

Research Team

  • Nikolaj Travica, BSc(Hons)

  • Bianca Fiasco

  • Michelle Brownstein

  • Prof Avni Sali

National Institute of Integrative Medicine (NIIM)
21 Burwood Road, Hawthorn VIC 3122 Australia

In collaboration with Broth & Co


Study Overview

The Bone Broth Gut Study was conducted to investigate the tolerability and effectiveness of Broth & Co Beef Bone Broth in Australian adults experiencing lower gastrointestinal disturbances.

The study evaluated digestive wellbeing, gastrointestinal symptoms, stool characteristics, quality of life and markers associated with intestinal permeability over a 12-week period.


Study Design

Type of Study

Prospective interventional single-arm clinical study with a pre-post design.

Participants

Adults experiencing moderate lower gastrointestinal disturbances.

Sample Size

30 Australian adults enrolled.

Duration

12 weeks total.

Phase 1: Run-In Period

4-week control period.

Phase 2: Intervention

8 weeks of Broth & Co Beef Bone Broth supplementation.

Participants consumed:

2 x 5g serves daily (10g total per day)

Mixed into warm water or incorporated into foods and beverages.


Outcome Measures

Researchers assessed:

Gastrointestinal Symptoms

Using validated symptom questionnaires including:

  • Birmingham IBS Symptom Questionnaire

  • IBS Quality of Life Questionnaire

Digestive Wellbeing

Assessment of:

  • Constipation

  • Diarrhoea

  • Urgency

  • Flatulence

  • Abdominal discomfort

Stool Characteristics

Using the Bristol Stool Chart:

  • Stool consistency

  • Stool frequency

  • Stool regularity

Quality of Life

Including:

  • Emotional wellbeing

  • Mental wellbeing

  • Energy

  • Sleep

  • Physical functioning

  • Social interactions

  • Dietary quality of life

Pain Assessment

Evaluation of:

  • Upper abdominal discomfort

  • Lower abdominal discomfort

  • Other pain symptoms

Intestinal Permeability

Using the Lactulose:Mannitol Test.


Understanding the Lactulose:Mannitol Test

The Lactulose:Mannitol Test is a recognised research tool used to assess intestinal permeability and gut barrier function.

The test measures how two non-metabolised sugars move across the intestinal lining:

Lactulose

A larger sugar molecule that is normally only minimally absorbed.

It is commonly used as a marker of intestinal barrier integrity.

Mannitol

A smaller sugar molecule that is more readily absorbed.

It is commonly used as a marker of transcellular uptake.

Lactulose:Mannitol Ratio

The Lactulose:Mannitol ratio is widely used in research investigating intestinal permeability.

Researchers continue to use this test to explore gut barrier function and digestive health outcomes.


Key Findings

Following eight weeks of Broth & Co Beef Bone Broth supplementation, researchers observed statistically significant improvements across several outcome measures.

1. Improvements in Gastrointestinal Symptoms

Participants demonstrated significant improvements in symptom severity including:

  • Constipation

  • Diarrhoea

  • Urgency

  • Flatulence

  • Abdominal discomfort

Overall symptom scores improved significantly.

(p < 0.0001)


2. Improvements in Quality of Life

Participants reported significant improvements in:

  • Emotional wellbeing

  • Mental wellbeing

  • Sleep

  • Energy levels

  • Physical functioning

  • Dietary quality of life

  • Social interactions

Overall quality-of-life scores improved significantly.

(p < 0.001)


3. Improvements in Upper Gastrointestinal Symptoms

Researchers observed significant improvements in symptoms including:

  • Indigestion

  • Heartburn

  • Regurgitation

  • Nausea

(p < 0.001)


4. Improvements in Stool Consistency

Stool consistency shifted towards the ideal Bristol Stool Chart Type 4 classification.

Participants experiencing both harder and looser stool types demonstrated improvement over the intervention period.


5. Improvements in Stool Regularity

Participants demonstrated improvements in stool frequency and regularity, moving closer to the commonly reported healthy range of one to two bowel motions per day.


6. Improvements in Pain Measures

Participants demonstrated significant reductions in:

  • Upper abdominal discomfort

  • Lower abdominal discomfort

  • Other reported pain symptoms

following eight weeks of supplementation.


7. Improvements in Markers Associated with Intestinal Permeability

Researchers observed significant improvements in markers associated with intestinal permeability among participants with elevated baseline levels.

Results included:

Lactulose Recovery

Improved by 33%

(p = 0.023)

Mannitol Recovery

Improved by 33%

(p = 0.006)

Lactulose:Mannitol Ratio

Improved by 25% in a subgroup of participants with elevated baseline values.

These findings indicate improvements in measures associated with intestinal permeability and gut barrier function.


Food Trigger Outcomes

At the commencement of the study, 25 participants reported one or more dietary triggers associated with digestive symptoms.

Researchers observed improvements in symptom severity associated with several commonly reported trigger foods.

FODMAP-Containing Foods

83% of participants reported improvements in symptoms associated with one or more FODMAP triggers.

Wheat and Gluten

36% of participants reported improved tolerance.

Acidic and Spicy Foods

36% of participants reported improvements.

Dairy Foods

27% of participants reported improved tolerance.

Fatty Foods

27% of participants reported improvements.

Alcohol

36% of participants reported improvements.


Clinical Significance

The Bone Broth Gut Study demonstrated statistically significant improvements in:

  • Gastrointestinal symptom severity

  • Quality of life

  • Stool consistency

  • Stool regularity

  • Pain measures

  • Markers associated with intestinal permeability

These findings contribute to the growing body of research investigating nutrient-dense foods and their role within broader digestive health and wellbeing strategies.


Conclusion

The Broth & Co Bone Broth Gut Study provides clinical evidence supporting the inclusion of Broth & Co Beef Bone Broth within dietary approaches focused on digestive wellbeing.

The study demonstrated significant improvements across multiple gastrointestinal and quality-of-life measures, together with improvements in markers associated with intestinal permeability.

Broth & Co Bone Broth Powder remains the only bone broth in Australia supported by a published clinical study investigating digestive wellbeing and intestinal permeability outcomes.

Important Note

This study investigated Broth & Co Beef Bone Broth as a food product within a dietary context. Individual results may vary. Bone broth should be consumed as part of a balanced diet and healthy lifestyle.

Learn More:

ブログに戻る